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ABSTRACT
Objective: To investigate a possible increased risk
observed in tiotropium clinical trials of stroke and
other adverse events.
Design: New users of long-acting anticholinergic
therapy (tiotropium HandiHaler) were compared with
new users of long-acting b-agonist (LABA)
monotherapy, and propensity scores were used to
control confounding.
Setting: UK healthcare system general practitioner
electronic medical record database.
Participants: 10840 patients newly prescribed
tiotropium (n¼4767) or LABA (n¼6073), at least
40 years old, and not having asthma as their only
respiratory illness.
Primary and secondary outcome
measures: Incidence rates of total stroke, myocardial
infarction, angina and other adverse events.
Results: Tiotropium was associated with increased
rates of stroke (HR¼1.49, 95% CI 0.91 to 2.45),
angina (HR¼1.38, 95% CI 0.88 to 2.16) and
myocardial infarction (HR¼1.26, 95% CI 0.72 to 2.21).
Groups had similar rates of chronic obstructive
pulmonary disease exacerbation (HR¼0.95, 95% CI
0.80 to 1.12) and pneumonia (HR¼0.96, 95% CI 0.58
to 1.58). Tiotropium was associated with a lower rate
of total mortality (HR¼0.70, 95% CI 0.56 to 0.89) and
asthma exacerbations (HR¼0.46, 95% CI 0.36 to 0.57)
than users of LABA.
Conclusion: Small increased risks of serious
ischaemic cardiovascular events have been reported
with inhaled anticholinergic medication from
randomised and nonrandomized studies of
ipratropium, tiotropium HandiHaler and tiotropium
Respimat. Additional research is needed to
understand the full extent of cardiovascular effects of
inhaled anticholinergic medications and the patients
who may be most susceptible.
INTRODUCTION
Inhaled anticholinergic medications,
including short-acting ipratropium bromide
(ipratropium) and long-acting tiotropium
bromide (tiotropium), are mainstays for the
treatment of symptoms of chronic obstructive
pulmonary disease (COPD). The safety
proﬁles of these drugs comprise systemic
anticholinergic events, including dry mouth,
constipation, urinary retention and cardiac
effects, including palpitations, tachycardia
and supraventricular tachycardia (SVT).
1e5
There has been concern that anticholinergic
drugs could induce ischaemia, possibly
secondary to tachyarrhythmias,
45and could
pose a risk to patients with cardiovascular
complications.
6 Among patients with
congestive heart failure, SVT is a risk factor
for stroke, as well as cardiovascular
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ARTICLE SUMMARY
Article focus
- This study investigated whether there are
possible increased risks of stroke and other
adverse events, including angina and myocardial
infarction, with tiotropium use in chronic
obstructive pulmonary disease.
- The authors compared new users of long-acting
anticholinergic therapy (tiotropium HandiHaler)
with new users of LABA monotherapy.
Key messages
- Compared with LABA, tiotropium HandiHaler was
associated with increased risks of angina,
myocardial infarction and stroke and lower risk
of total mortality.
- The results of this study are similar to results
from a recent clinical trial comparing tiotropium
with salmeterol and support the hypothesis that
tiotropium HandiHaler can be associated with an
increased risk of ischaemic cardiovascular
events.
Strengths and limitations of this study
- Strengths of this study are the new user design
and use of propensity scores to control for
available risk factors, including demographic
factors, history of respirator, cardiovascular
and other illness and respiratory, cardiovascular
and other medications.
- Limitations of this study are that routine lung
function measures were unavailable, and
composite end points of all-cause mortality and
all strokes may attenuate associations for
cardiovascular mortality and ischaemic stroke.
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Open Access Researchhospitalisation and death.
7 Furthermore, among
patients with sinus node dysfunction, asymptomatic
atrial tachyarrhythmias increase the risk of stroke and
death.
8
We conducted this epidemiologic study to examine the
possible association between tiotropium (HandiHaler
powder formulation) and risk of stroke and other
cardiovascular adverse events, including angina and
myocardial infarction (MI).
METHODS
Treatment guidelines for COPD consider long-acting
bronchodilators as a class and make no distinction
between anticholinergic drugs and long-acting b agonists
(LABAs), resulting in clinical equipoise.
9 Therefore, new
users of tiotropium were compared with new users of
LABAs.
10 11 Both long-acting bronchodilators are indi-
cated for treating symptoms of COPD; LABAs are also
indicated for the treatment of asthma.
The source population included patients in the UK
enrolled with a general practitioner who contributes to
The Health Improvement Network (THIN) primary care
database. The THIN database includes deidentiﬁed
patient records containing demographic data, medical
history, prescribed medications, diagnostic tests, labora-
tory results, specialist referrals and some lifestyle char-
acteristics.
12 The database is derived from the same
software as the General Practice Research Database and
has been validated for COPD, as well as stroke and MI,
and is widely used in epidemiologic research.
12e14
Patients had to have at least one prescription for
tiotropium (HandiHaler formulation) or LABA (salme-
terol or formoterol) from November 2002 (the earliest
use of tiotropium) until January 2007. Because
tiotropium is available only in a single-ingredient prep-
aration, whereas LABAs are also available in combina-
tion with inhaled corticosteroids, the LABA group was
restricted to patients prescribed single-ingredient
LABAs. Patients had to have at least two years of baseline
data with no use of a long-acting inhaler prior to their
ﬁrst or “index” prescription for tiotropium or LABA. To
reduce confounding by indication, patients who had
a recorded diagnosis of asthma as their only respiratory
diagnosis were excluded, as were patients less than 40
years old.
Study end points included various cardiovascular
adverse events (aneurysm, atrial ﬁbrillation, cardiac
arrest, coronary artery disease, angina, MI, heart failure,
hypertension, stroke, syncope, tachycardia and ventric-
ular tachycardia), respiratory adverse events (COPD
exacerbation, asthma exacerbation and pneumonia)
and other adverse events of interest (constipation, dry
mouth, dysphagia, paralytic ileus/bowel obstruction,
renal failure, tremor, urinary retention). Information on
causes of death was unavailable, but we were able to
examine all-cause mortality. Most end points were
deﬁned using medical codes from the Read Clinical
Classiﬁcation Version 2, May 2006. Mortality was identi-
ﬁed from a combination of READ codes, registration
status, additional health data codes and enrolment
dates.
Covariates were selected for inclusion in the analysis
based on clinical importance and included respiratory
diagnosis (COPD/no asthma, COPD and asthma, other
(ie, asthma or COPD not recorded)), age, sex, calendar
year of drug start, smoking, body mass index, number of
hospitalisations in the year prior to cohort entry, number
of general practitioner visits in the year prior to cohort
entry, cardiac comorbidities (ischaemic heart disease,
arrhythmias, hypertension), respiratory medications
(number of prescriptions for short-acting anticholiner-
gics, short-acting b-agonists, inhaled corticosteroids, oral
corticosteroids and use of theophyllines and cromogly-
cates), cardiac medications (prescriptions for anti-
arrhythmics, anticoagulants, anti-hypertensives, ACE
inhibitors, diuretics, inotropics, lipid regulators, b-
blockers, nitrates), other medications (gastrointestinal,
vascular, central nervous system, infectious disease,
endocrine, gynaecologic/urinary tract, malignancy,
nutrition/blood disorders), oxygen use, lung cancer
diagnosis prior to index and history of diabetes.
People were classiﬁed as exposed to study medication
for the duration of prescribed therapy plus 30 days. For
the analysis of each end point, patients were followed
from the date of their ﬁrst eligible prescription until the
earliest of the following: date of treatment end, date of
study end point, date of transfer to a new practice, death
or January 2007. Each end point was analysed separately,
so patients who experienced more than one end point
under study were included in analyses of each event.
Incidence rates of the study end points were calculated
as the number of patients experiencing an event divided
by the person-years at risk. Incidence rate ratios were
calculated as the incidence rate in the tiotropium group
divided by the incidence rate in the LABA group.
Precision of effect estimates was evaluated from the
width of the 95% CIs.
15
Some end points were rare relative to the number of
factors that needed to be controlled, so propensity
scores (derived from logistic regression models) were
used to enhance efﬁciency of analytic control of
confounding.
16 The propensity score is the estimated
chance of a patient receiving tiotropium compared with
LABA, given a patient’s observed set of covariates
(prognostic variables). In constructing the logistic
models used to calculate the propensity scores, all
available variables described above were entered into the
model.
Multivariate analysis was performed using Cox’
proportional hazard model with adjustment for indica-
tors of propensity score quintile to estimate adjusted
HRs and corresponding 95% CIs.
17 The assumption of
proportionality of the hazards was tested by including
time-dependent covariates in the Cox model.
17 We also
computed effect estimates using Poisson regression.
Effect estimates are presented for end points where the
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treatment group.
To identify a study population of more compliant long-
term users, we also conducted analyses restricted to
patients on treatment for greater than 6 months. In
addition, analyses were stratiﬁed by respiratory diag-
nostic status (COPD and asthma, COPD without asthma,
other), use of oral corticosteroids and history of coro-
nary artery disease.
All analyses were performed using STATA V.7.0 and
SAS V.9.1. This study received ethical approval from the
UK Department of Health Multicentre Research Ethics
Committee.
RESULTS
The study population included 4767 tiotropium patients
and 6073 LABA patients who contributed 2775 person-
years of exposure to tiotropium and 2303 person-years of
exposure to a single-ingredient LABA (table 1). Mean
duration of exposure was 212 days for tiotropium
patients and 139 days for LABA patients. Ninety-ﬁve per
cent of LABA prescriptions were for salmeterol. Though
a similar proportion of tiotropium and LABA patients
switched or added a different long-acting bronchodilator
thereby terminating study participation, a lower
proportion of tiotropium patients than LABA patients
discontinued use of a long-acting bronchodilator prior
to the administrative end of the study (58% compared
with 73%). The proportion of current smokers was
slightly higher in tiotropium users than in LABA users
(37% compared with 30%). Other covariates were
generally balanced between treatment groups.
Characteristics of medical history prior to study entry
are shown in table 2. A high proportion of patients in
both groups had spirometry testing (89% of tiotropium
patients and 84% of LABA patients) and a diagnosis of
COPD (89% of tiotropium patients and 88% of LABA
patients). More LABA patients than tiotropium patients
also had an asthma codiagnosis (42% vs 63%).
Results from Cox models and Poisson models were
similar, so estimates from Cox models are presented
(table 3). There were small increases in the tiotropium
group in the rates of angina (HR¼1.38, 95% CI 0.88 to
2.16), MI (HR¼1.26, 95% CI 0.72 to 2.21) and stroke
(HR¼1.49, 95% CI 0.91 to 2.45). There were similar rates
between treatment groups of aneurysm (HR¼0.96, 95%
CI 0.44 to 2.05), atrial ﬁbrillation or ﬂutter (HR¼0.99,
95% CI 0.71 to 1.38), coronary artery disease (HR¼1.11,
95% CI 0.84 to 1.47), hypertension (HR¼1.03, 95% CI
0.81 to 1.29), syncope (HR¼0.94, 95% CI 0.57 to 1.55)
and tachycardia (HR¼1.08, 95% CI 0.48, 2.41). There
was a decrease in the tiotropium group in the rate of
heart failure (HR¼0.85, 95% CI 0.63 to 1.14) and all-
cause mortality (HR¼0.70, 95% CI 0.56 to 0.89).
With regard to respiratory events, there was a lower
rate of asthma exacerbation in patients using tiotropium
compared with patients using a LABA (HR¼0.46, 95%
CI 0.36 to 0.57). There were similar rates of COPD
exacerbations (HR¼0.95, 95% CI 0.80 to 1.12) and
pneumonia (HR¼0.96, 95% CI 0.58 to 1.58).
Dry mouth was recorded at a higher rate in patients
using tiotropium compared with patients using a LABA
(HR¼3.66, 95% CI 1.52 to 8.78). The rate of constipa-
tion (HR¼0.95, 95% CI 0.74 to 1.23), dysphagia
(HR¼1.02, 95% CI 0.62 to 1.69) and urinary retention
(HR¼0.97, 95% CI 0.55 to 1.70) was similar in both
treatment groups. There was a higher rate of renal
failure in tiotropium patients (HR¼1.40, 95% CI 0.77 to
2.55) and a lower rate of tremor (HR¼0.62, 95% CI 0.31
to 1.22).
Among patients who had been receiving long-acting
bronchodilator therapy for at least 6 months, effect
estimates increased for stroke (HR¼1.63, 95% CI 0.83 to
3.17), angina (HR¼1.42, 95% CI 0.78 to 2.59) and MI
(HR¼1.65, 95% CI 0.63 to 4.27). The difference between
groups in rates of total mortality diminished (HR¼0.90,
95% CI 0.58 to 1.38). Associations for other cardiovas-
cular events were weaker, including aneurysm
(HR¼0.82, 95% CI 0.27 to 2.45), atrial ﬁbrillation/
ﬂutter (HR¼1.17, 95% CI 0.70 to 1.94), heart failure
(HR¼0.77, 95% CI 0.47 to 1.24), hypertension
(HR¼1.07, 95% CI 0.79 to 1.45), syncope (HR¼0.79,
95% CI 0.36 to 1.70) and tachycardia (HR¼0.98, 95% CI
0.32 to 3.04).
Effect estimates for respiratory end points among
patients treated for at least 6 months were similar to those
in the total population (asthma exacerbation (HR¼0.47,
95% CI 0.33 to 0.65), COPD exacerbation (HR¼0.82,
Table 1 Demographic characteristics of the study
population
Tiotropium,
n=4767
LABA*,
n=6073
n% n%
Age group
40e49 149 3 362 6
50e59 641 13 943 16
60e69 1391 29 1730 28
70e79 1759 37 1991 33
80e89 769 16 976 16
90+ 58 1 71 1
Sex
Male 2707 57 3073 51
Female 2060 43 3000 49
Body mass index
Low 634 13 613 10
Normal 1500 31 1799 30
Overweight 1413 30 1895 31
Obese 1012 21 1467 24
Missing 208 4 299 5
Smoking
Never 562 12 1077 18
Current 1765 37 1812 30
Former 2343 49 2960 49
Missing 97 2 224 4
*Long-acting b-agonist single-ingredient formulations.
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Safety of long-acting bronchodilators in COPD95% CI 0.63 to 1.05) and pneumonia (HR¼1.42, 95% CI
0.68 to 2.96)). Effect estimates computed for other events
included constipation (HR¼0.97, 95% CI 0.69 to 1.37),
dysphagia (HR¼1.30, 95% CI 0.65 to 2.58), renal failure
(HR¼1.17, 95% CI 0.51 to 2.66), urinary retention
(HR¼1.17, 95% CI 0.51 to 2.66) and tremor (HR¼0.57,
95% CI 0.23 to 1.41).
After stratifying by subgroups, results were imprecise
and generally similar to the overall results. With regard to
concomitant asthma diagnosis, the association with
angina was stronger in patients with asthma and COPD
(HR¼1.91, 95% CI 1.00 to 3.63) than patients with only
COPD (HR¼0.93, 95% CI 0.49 to 1.77), while the asso-
ciation with MI was stronger in patients who had only
COPD (HR¼1.94, 95% CI 0.77 to 4.94). Asthma exacer-
bations occurred only among patients with a concomitant
diagnosis of asthma. After stratiﬁcation by coronary artery
disease, the association with angina was stronger among
patients without coronary artery disease (HR¼3.02, 95%
CI 1.08 to 8.47) than among patients with coronary artery
disease (HR¼1.05, 95% CI 0.63 to 1.77). After stratiﬁca-
tion by corticosteroids, the association with angina was
greater among patients without corticosteroids
(HR¼2.28, 95% CI 0.99 to 5.26) than with corticosteroids
(HR¼1.09, 95% CI 0.63, 1.89), while the association with
stroke was greater for patients with corticosteroids
(HR¼1.85, 95% CI 1.00 to 3.44) than without cortico-
steroids (HR¼0.86, 95% CI 0.37 to 2.01).
DISCUSSION
This study found small increased risks of stroke, MI and
angina along with a decreased risk of mortality with
Table 2 Medical history of the study population by long-acting bronchodilator
Tiotropium, n=4767 LABA*, n=6073
n% n%
Prior respiratory diagnosis
COPD and asthma 1807 38 3366 55
COPD only 2450 51 1960 32
Other 510 11 747 12
Use of respiratory medicationsy
Short-acting anticholinergics 1948 41 2372 39
Short-acting b-agonists 3372 71 5053 83
Inhaled corticosteroids 1904 40 3610 59
Oral corticosteroids 1396 29 2227 37
Theophyllines 238 5 361 6
Cromoglycates 48 1 67 1
Use of oxygen 187 4 175 3
Use of cardiac medicationsy
Anti-arrhythmics 219 5 312 5
Anti-coagulants 1834 38 2069 34
Anti-hypertensives 2424 51 2913 48
ACE inhibitors 1162 24 1380 23
Diuretics 1912 40 2336 38
Inotropics 254 5 286 5
Lipid regulators 1413 30 1509 25
b-Blockers 613 13 537 9
Nitrates 704 15 843 14
History of ischaemic heart disease 233 5 319 5
History of arrhythmia 139 3 165 3
History of hypertension 1785 37 2202 36
History of diabetes 456 10 591 10
Use of spirometry (at least once) 4225 89 5093 84
Number of general practitioner visitsy
0 357 6 288 7
1e5 2167 45 2577 42
6e10 1415 30 1902 31
11+ 897 19 1237 20
Number of hospital admissionsy
0 4143 87 5097 84
1e2 502 11 791 13
3+ 122 3 185 3
*Single-ingredient formulations.
y365 days prior to index date.
COPD, chronic obstructive pulmonary disease; N, number; LABA, long-acting b-agonists.
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identify with certainty associations between speciﬁc
medications and rare adverse events, and these ﬁndings
should be considered in context with other evidence.
In 2002, the Lung Health Study, the ﬁrst large placebo-
controlled randomised trial of an inhaled anticholin-
ergic agent reported an increased incidence in the
ipratropium group of hospitalisation due to SVT, angina,
MI and death due to coronary heart disease.
18 Obser-
vational studies have reported associations between
ipratropium and stroke,
19 cardiovascular hospital-
isation
20 and death.
21
Tiotropium has a similar mechanism of action to
ipratropium, and in 2008, the FDA issued an early
communication after a pooled analysis of placebo-
controlled clinical trials revealed an excess risk of stroke
with tiotropium.
22 Subsequently, the Uplift trial reported
a decreased risk of total mortality, MI and no increased
risk of stroke with tiotropium.
23 As in other studies, the
stroke end point was a composite end point that
included ischaemic and hemorrhagic stroke,
23 and the
incidence of ischaemic stroke in the Uplift study was
slightly greater in the tiotropium group than the placebo
group.
24 25 In addition, the Uplift study showed an
increased risk with tiotropium of certain tachyarrhyth-
mias
26 and serious angina.
23
A pooled analysis of randomised trials reported an
increased rate of arrhythmias with tiotropium compared
with placebo or LABAs and increased risks with
tiotropium of both cardiovascular and cerebrovascular
serious adverse events (RR¼1.71, 95% CI 0.76 to 3.89).
27
A randomised trial comparing tiotropium with salme-
terol in combination with ﬂuticasone reported increased
cardiac adverse events with tiotropium.
28 An observa-
tional study reported increased risk of mortality with
tiotropium compared with LABA.
29 Pooled analyses of
placebo-controlled tiotropium clinical trials have
reported small increased rates with tiotropium of palpi-
tations, SVT, angina and stroke and lower rates of MI,
cardiovascular mortality and total mortality.
30e32
Perhaps the most relevant study is the recent ‘POET’
study, the largest tiotropium randomised trial conducted
to date, with 7376 COPD patients.
33 The POET Study is
similar to this study in that, it compared tiotropium
HandiHaler with salmeterol. The POET Study also
found fewer deaths for tiotropium (n¼64) compared
with salmeterol (n¼78), although there was no decrease
in cardiac deaths (eight tioptropium vs six salmeterol)
33
Table 3 Incidence rates and adjusted rate ratio estimates in new users of long-acting bronchodilators
Adverse events
Tiotropium, n[4767 LABA,* n[6073 Crude Adjusted
n Pyrs Ratey n Pyrs Rate RR HR 95% CI
Death (any) 152 2775 5.48 170 2303 7.38 0.74 0.70 0.56 to 0.89
Cardiovascular
Aneurysm 17 2765 0.61 13 2298 0.57 1.09 0.96 0.44 to 2.05
Atrial ﬁbrillation/ﬂutter 87 2725 3.19 76 2272 3.34 0.95 0.99 0.71 to 1.38
Cardiac arrest 3 2774 0.11 4 2303 0.17 0.65 ──
Coronary artery disease 125 2712 4.61 102 2255 4.52 1.02 1.11 0.84 to 1.47
Angina 53 2746 1.93 38 2275 1.67 1.16 1.38 0.88 to 2.16
Myocardial infarction 35 2765 1.27 23 2297 1.00 1.26 1.26 0.72 to 2.21
Heart failure 93 2738 3.40 105 2265 4.64 0.73 0.85 0.63 to 1.14
Hypertension 169 2654 6.37 163 2232 7.30 0.87 1.03 0.81 to 1.29
Stroke 45 2750 1.64 28 2296 1.22 1.34 1.49 0.91 to 2.45
Syncope 35 2762 1.27 35 2289 1.53 0.83 0.94 0.57 to 1.55
Tachycardia 15 2769 0.54 11 2296 0.48 1.13 1.08 0.48 to 2.41
Ventricular tachycardia 2 2774 0.07 1 2302 0.04 1.66 ──
Respiratory
Asthma exacerbation 98 2716 3.61 395 2140 18.46 0.20 0.46 0.36 to 0.57
COPD exacerbation 287 2637 10.88 313 2168 14.44 0.75 0.95 0.80 to 1.12
Pneumonia 35 2757 1.27 34 2297 1.48 0.86 0.96 0.58 to 1.58
Other
Constipation 137 2708 5.06 124 2251 5.51 0.92 0.95 0.74 to 1.23
Dry mouth 26 2762 0.94 7 2299 0.30 3.09 3.66 1.52 to 8.78
Dysphagia 39 2757 1.41 32 2292 1.40 1.01 1.02 0.62 to 1.69
Paralytic ileus/bowel obstruction 4 2775 0.14 7 2301 0.30 0.47 ──
Renal failure 34 2760 1.23 19 2295 0.83 1.49 1.40 0.77 to 2.55
Urinary retention 29 2765 1.05 25 2290 1.09 0.96 0.97 0.55 to 1.70
Tremor 16 2769 0.58 23 2292 1.00 0.58 0.62 0.31 to 1.22
*Single-ingredient formulations.
yRate per 100 person-years.
‘─’ signiﬁes the adjusted results are not presented as there are <5 events in either tiotropium or LABA users.
COPD, chronic obstructive pulmonary disease; LABA, long-acting b-agonists; N, number of patients; Pyrs, person-years at risk; RR, rate ratio;
HR, relative hazard estimated using Cox’ proportional hazards model adjusted for propensity score.
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no increased risk of stroke but found an increased risk
with tiotropium of several serious cardiovascular adverse
events including angina (nine tiotropium vs ﬁve salme-
terol), myocardial ischaemia (11 tiotropium vs six
salmeterol) and MI (20 tiotropium vs 13 salmeterol).
33 34
Recently, safety concerns have been raised about
increased mortality with the mist inhaler formulation of
tiotropium (Respimat), which is available in several
countries but which was not approved for marketing in
the USA.
35 (Tiotropium Respimat was not available in
the UK at the time of this analysis.) It was hypothesised
that the increased risk of deaths, which were mostly
cardiac and sudden or unexplained deaths, may be the
result of the device delivering a greater dose than the
powder formulation.
36 Tiotropium Respimat is also
associated with a dose-related increased risk of angina
and cardiac ischaemic events, but not MI.
37 38
The decreased risk of mortality observed in this study
with tiotropium is in agreement with the results reported
in the Uplift
23 and POET
33 studies, but not in the ipra-
tropium Lung Health Study
18 or several large tiotropium
trials using the Respimat device.
37 39 These drugs have
virtually identical safety proﬁles,
234 0so it would be an
oversimpliﬁcation to suggest that they have either
beneﬁcial or harmful effects on mortality based solely on
the device delivering similar active ingredients. Hetero-
geneity of results should be considered in light of both
causal and non-causal explanations. For composite end
points, interpretation often can be clariﬁed by evalu-
ating components, especially cardiovascular deaths.
Thus, the POET Study reports fewer total deaths with
tiotropium
33 but more cardiac deaths.
34
The results for angina, MI and stroke reported here
and in other studies of inhaled anticholinergic drugs are
usually not statistically signiﬁcant. The absence of
statistical signiﬁcance in studies that lack the power to
detect small effects should be expected and does not
indicate the absence of an effect.
41 42 For instance,
repeated ﬁndings of an increased risk of angina of
a similar magnitude in studies of different design and
locations make chance an unlikely explanation for this
ﬁnding.
Non-randomized studies must always be concerned
with possible bias arising from differences in baseline
risks between treatment groups. We used propensity
scores and multivariate models to control efﬁciently for
available risk factors. Nevertheless, certain variables,
such as lung function results, were unavailable and could
not be controlled. We found that more LABA patients
than tiotropium patients had an asthma diagnosis in
addition to their COPD diagnosis. The decreased risk of
asthma exacerbations in the tiotropium group is
consistent with a greater proportion of patients in the
LABA group having an asthma component to their
COPD. Nevertheless, COPD diagnoses and exacerba-
tions were similar between groups, suggesting similar
severity of COPD. Nevertheless, it is possible that
tiotropium patients had more severe COPD than LABA
patients despite our efforts to control for baseline risk
factors. More severe COPD might account for higher
rates of cardiovascular events, although the decreased
mortality in the tiotropium group is inconsistent with
this hypothesis. Increased risks of ischaemic cardiovas-
cular events in randomised trials also argue against
confounding as an explanation.
All tiotropium effect estimates in this study are relative
to effects of LABA. A valid effect estimate indicating
a higher rate with tiotropium means that tiotropium
increases risk more than LABA but both drugs could be
either increasing or decreasing risk. To the extent that
LABA may increase the risk of cardiovascular adverse
events, such an effect would attenuate an increased risk
that might also exist for tiotropium.
Among non-cardiovascular and non-respiratory end
points, results showed an increased risk of dry mouth
with tiotropium, but not for other anticholinergic end
points including constipation and urinary retention. The
incidence of these less serious events was low; however,
and it is likely that only a small proportion of these cases
are reported to GPs and recorded in the database.
Under-reporting of non-serious AEs could introduce
misclassiﬁcation that would dilute RR estimates for
events such as dry mouth and constipation.
15 Misclassi-
ﬁcation could have occurred for more serious end points
as well, although we would expect that completeness of
the medical record would be better for more serious
cardiovascular events. Misclassiﬁcation of certain serious
end points still is a concern, however, as we examined
total mortality and total strokes, but not cardiovascular
mortality or ischaemic strokes. Finally, tiotropium
HandiHaler is available in one dose, and this study was
unable to evaluate doseeresponse. However, among
patients using therapy for at least 6 months, the associ-
ations with angina, MI and stroke became stronger, while
the association with mortality became weaker.
Results of this study should be interpreted cautiously,
but they lend modest support to a considerable body of
evidence of a serious cardiovascular safety risk with
inhaled anticholinergic drugs. Nevertheless, with regard
to safety of inhaled anticholinergic drugs, the FDA
recently concluded that ‘data from Uplift adequately
addressed the potential safety signal of stroke and adverse
cardiovascular outcomes.’
43 A few points help explain
these divergent conclusions. First, we consider the entire
body of evidence pertaining to class effects, and we
consider each study on its merits. In particular, studies
should not be disregarded merely because they are not
randomised
19e21 29 or they include an another medica-
tion as a control group instead of a placebo group.
28 33
Second, when considering the evidence pertaining to
small effects on rare adverse events, we do not assume
that results that are not statistically signiﬁcant provide
evidence against an increased risk.
41 42 This is especially
important when increases in risk are small or studies were
not large enough to detect such risks as statistically
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effect estimates and the precision with which they are
measured.
41 42 The Uplift study, for instance, describes
higher rates of serious angina and ischaemic stroke with
tiotropium than placebo
24 and so can hardly provide
reassurance about the absence of such risks. In addition,
results from composite end points do not necessarily
apply to each of their components. Thus, decreased rates
of total mortality and total stroke can mask increased rates
of cardiovascular mortality
24 or ischaemic stroke.
34 Finally,
adverse effects do not occur in every patient and may not
be apparent in every population or every study. Hetero-
geneity of results is not evidence against a causal effect
but is an interesting ﬁnding that should be interpreted in
consideration of the impact of both non-causal as well as
causal explanations; the latter include differences in
populations, durations of follow-up and doses. Thus, the
absence of an increased risk of MI in the Uplift study does
not negate increases in risk of MI in the Lung Health
Study,
18 POET Study
34 or this study, especially when each
of these studies indicates an increased risk of angina.
Inhaled anticholinergic drugs are effective treatments
in COPD and treatment decisions must balance beneﬁts
with risks for individual patients. It has long been
suggested that older people are especially susceptible to
anticholinergic effects, and angina has been described
previously as a severe anticholinergic effect secondary to
tachyarrhythmias.
1 45Subsequently, increased risks of
tachyarrhythmias and angina have been reported in
association with inhaled anticholinergic drugs in non-
randomised and randomised studies, of various sizes and
durations, with ipratropium and tiotropium, compared
with placebo and active comparators, and using different
devices. Pharmacological and clinical evidence, there-
fore, supports these cardiovascular events as class effects
of inhaled anticholinergic drugs. Small increased rates
of stroke have been observed fairly consistently across
studies, while MI, and cardiovascular death, have been
associated in different studies both positively and nega-
tively with anticholinergic medication. Additional
research is needed to understand the full extent of
cardiovascular effects of inhaled anticholinergic medi-
cations and the patients who may be susceptible.
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